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SUPPLEMENTARY METHODS
Harvard NHS & HPFS set
Description of eight GWAS study populations of 
the NHS & HPFS set
1) Postmenopausal invasive breast cancer case-
control study nested within the NHS (CGEMS): Eligible 
cases in this study consisted of women with pathologically 
confirmed incident breast cancer from the sub-cohort 
who gave a blood specimen. Cases with a diagnosis after 
blood collection up to June 1, 2000 with no previously 
diagnosed cancer except for non-melanoma skin cancer 
were included. One control for each case was randomly 
selected among women who gave a blood sample and 
were free of diagnosed cancer (excluding non-melanoma 
skin cancer) up to and including the interval in which the 
case was diagnosed. Controls were matched to cases on 
year of birth, menopausal status, recent post-menopausal 
hormone (PMH) use, month of blood return, time of day 
of blood collection, and fasting status at blood draw [1].
2) Type 2 diabetes (T2D) case-control study nested 
within the NHS and HPFS (T2D_NHS and T2D_HPFS): 
Diabetes cases were defined as self-reported incident 
diabetes confirmed by a validated supplementary 
questionnaire. For cases before 1998, diagnosis was 
made using criteria consistent with those proposed 
by the National Diabetes Data Group (NDDG). For 
cases during the 1998 and 2000 cycles, the American 
Diabetes Association’s diagnostic criteria were used for 
the diagnosis of diabetes cases. The non-diabetic control 
subjects were matched to cases on age, month and year of 
blood draw, and fasting status [2].
3) Coronary heart disease (CHD) case-control 
study nested within the NHS and HPFS (CHD_NHS and 
CHD_HPFS): In both the NHS and HPFS, participants 
who had reported an incident CHD event on the follow-
up questionnaire were contacted for confirmation, and 
permission to review medical records was requested. 
Medical records for deceased participants were also sought 
for deaths that were identified by families and postal 
officials and through the National Death Index. Physicians 
blinded to the participant’s questionnaire reports reviewed 
all medical records. Fatal CHD cases were identified 
primarily through review of medical records, as previously 
described [3]. Among participants who provided blood 
samples and who were without cardiovascular disease 
or cancer at blood draw, incident CHD cases occurring 
after blood draw were selected as cases. Controls were 
selected, in a 2:1 ratio matched to cases on age, smoking, 
and month of blood return.
4) Kidney stone study nested within the NHS and 
HPFS (KS_NHS_HPFS): Participants from the KS_
NHS_HPFS were individuals who performed a 24-hour 
urine collection; two-thirds had a history of incident 
nephrolithiasis. Details regarding the urine collection 
[4] and the confirmation of kidney stone disease were 
published previously [5]. The participants reported on 
the interval diagnosis of kidney stones every 2 years. 
Any study participant who reported a new kidney stone 
was sent an additional questionnaire to determine the 
date of occurrence and the symptoms produced by the 
stone.
5) Prostate cancer study nested within the HPFS 
(ADVCAP_HPFS): Prostate cancer cases are matched to 
controls on birth year (+/−1) and ethnicity. Controls are 
selected from those who are cancer-free at the time of the 
case’s diagnosis, and had a prostate- specific antigen test 
after the date of blood draw.
6) Glaucoma: Primary open angle glaucoma cases 
were defined as self-reported incident glaucoma confirmed 
to be primary open angle glaucoma with reproducible 
visual field loss confirmed with standardized visual field 
tests and validated supplementary questionnaires or 
medical records from diagnosing eye care providers. Cases 
were all Caucasian and matched to controls (roughly 1:1) 
on cohort, age, type of sample (blood or cheek cell).
7) PANSCAN: Subjects were followed prospectively 
with repeated assessments of lifestyle factors and 
ascertainment of cancer diagnoses. Each cohort study 
selected participants with blood or buccal cells collected 
before cancer diagnosis. One control was selected per case 
within each cohort. Controls were matched on year of 
birth (± 5 years), gender, self-reported race/ethnicity, and 
source of DNA (peripheral blood or buccal cells). Controls 
were alive without pancreatic cancer on the incidence date 
of the matched case [6].
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Quality control (QC) procedures for eight GWAS 
of the NHS & HPFS set
1) CGEMS: Detailed QC procedures were provided 
previously [1]. Briefly, a total of 555,352 SNP genotype 
assays were attempted on the 2,494 DNA samples 
using the Illumina HumanHap550 chip. Whenever the 
completion rate for a sample was below 90%, the sample 
was assayed a second time. Samples that did not meet the 
90% completion threshold after a second attempt were 
excluded from further analysis. We excluded 59 samples 
from NHS (30 cases and 29 controls) from further analysis 
based on these criteria, which left 2,435 DNAs for the 
subsequent analyses.
A total of 8,706 SNPs (~1.57% overall) failed to 
provide accurate genotype results owing to either a lack 
of calls or low call rates (< 90%). We performed further 
quality control analysis on the remaining 546,646 SNPs. 
The genotyping of the SNPs with high call rate on the 
2,412 NHS DNAs with high completion rate generated 
1.27 billion genotype calls. For this set of SNPs and 
samples, the percentage of missing data was < 1%. The 
genotype concordance rate for SNP assays was evaluated 
using the 93 pairs of known duplicated DNAs from the 
NHS. These pairs of DNAs were separate aliquots from 
the same DNA preparation; all met quality control criteria 
required for the other DNAs, thereby providing reliable 
data for comparison. Analysis of the discrepancies within 
these pairs of DNA uncovered results similar to those of 
the Centre d’Etude du Polymorphisme Humain (CEPH) 
DNA duplicates reported in the prostate cancer CGEMS 
GWAS [7]. We observed an average concordance rate of 
99.985% (50,820,003 concordant genotype calls out of 
50,827,468 comparisons).
2) T2D_NHS and T2D_HPFS: Detailed QC 
procedures were provided previously [2]. Briefly, the NHS 
and HPFS T2D GWA scans are a component of the Gene 
Environment- Association Studies (GENEVA) under the 
NIH Genes, Environment and Health Initiative (GEI). 
Genotypic data first passed Broad’s initial QC which 
included SNP fingerprints for sample tracking and early 
detection of sample misidentification, missing call rates 
of ≥ 5%, the use of a HapMap control to check genotype 
quality independent of study samples and tracking of 
reagent and instrumental performance.
Genotype data were subsequently released for 
further QC to the GENEVA Coordinating Center at the 
University of Washington. Relatedness was evaluated 
using pairwise identity-by descent estimation using 80k 
SNPs in a method of moments approach implemented in 
PLINK software [8]. Of the 909,622 SNP probes on the 
array, 879,071 passed the Broad’s technical QC standards 
for NHS samples, and 874,517 SNP probes passed this 
QC stage for HPFS samples. We applied the same QC 
parameters to both scans: excluding SNPs which were 
monomorphic, had a missing call rate of ≥ 2%, more 
than one discordance, significant deviations from HWE 
(P < 1 × 10−4) and an MAF of < 0.02. Duplicate SNPs 
(assayed with different probes) were also removed. A total 
of 704,409 SNPs for NHS samples and 706,040 SNPs for 
HPFS samples passed QC.
3) CHD_NHS and CHD_HPFS: QC procedures 
for CHD_NHS and CHD_HPFS were similar to those 
used for T2D. Briefly, PLINK software [8] was used 
for data cleaning. The data were cleaned separately for 
NHS and HPFS according to thresholds recommended 
by the GENEVA consortia described above. We excluded 
SNPs that met any of following criteria: 1) MAF < 0.02; 
2) call rate < 95%; 3) P for Hardy-Weinberg equilibrium 
HWE < 0.00001 in control groups; 4) concordance rate 
< 95% among the duplicated QC samples; 5) significant 
difference in missing rates between cases and controls 
(P < 0.00001). After applying the QC filter, 721,316 SNPs 
remained for NHS and 724,881 for HPFS.
4) KS: All samples were highly genotyped. SNPs 
with MAF < 1.0% in either cases or controls were 
removed, as were SNPs with less than 97% completion in 
cases or controls or any SNP with HWE-test p < 10−4.
5) ADVCAP_HPFS: Samples were excluded if the 
genotyping call rate was ≤ 95%. Samples with autosomal 
heterozygosity < 0.25 or > 0.35 were excluded. SNPs with 
MAF < 2.5% in either cases or controls were removed, 
as were SNPs with less than 95% completion in cases 
or controls or any SNP with HWE-test p < 10−5. We had 
519,982 SNPs after filtering.
6) GLAUCOMA: Samples were excluded if the 
genotyping call rate was ≤ 97%. SNPs with MAF < 1.0% 
in either cases or controls were removed, as were SNPs 
with less than 95% completion in cases or controls.
7) PANSCAN: Samples were excluded if the 
genotyping call rate was ≤ 97%, no other filter.
8) MELANOMA: SNPs with MAF < 1.0% in either 
cases or controls were removed, as were SNPs with less 
than 97% completion in cases or controls or any SNP with 
HWE- test p < 10−4. 
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Supplementary Table S2: Association between smoking behaviors–related SNPs and melanoma 
risk in each data set
NHS and HPFS set MD Anderson set
SNP CHR Gene Risk Ref Allele frequency OR P OR P
rs215605a 7 PDE1C G T 0.38 0.96 0.54 1.04 0.50
rs11782673b 8 PTK2B G A 0.17 1.16 0.09 1.04 0.62
rs6474412a 8 SMIM19, CHRNB3 C T 0.23 1.06 0.43 1.00 0.97
rs13280604a 8 CHRNB3 G A 0.23 1.06 0.44 0.99 0.89
rs7872903a 9 FAM163B, DBH C T 0.21 1.07 0.41 0.96 0.52
rs1329650a 10 HECTD2-AS1 T G 0.28 0.96 0.54 0.98 0.76
rs1013442a 11 BDNF-AS T A 0.25 1.00 0.98 1.04 0.59
rs6265a 11 BDNF T C 0.19 1.05 0.59 1.04 0.58
rs2036534b 15 HYKK C T 0.22 1.14 0.10 1.14 0.06
rs588765b 15 CHRNA5 T C 0.42 1.03 0.62 1.02 0.78
rs16969968a 15 CHRNA5 A G 0.35 0.87 0.05 0.93 0.22
rs578776a 15 CHRNA3 A G 0.28 1.16 0.03 1.02 0.73
rs1051730a 15 CHRNA3 A G 0.34 0.89 0.11 0.93 0.22
rs6495308a 15 CHRNA3 C T 0.23 1.13 0.12 1.05 0.43
rs7937a 19 MIA-RAB4B C T 0.44 0.89 0.08 0.97 0.61
rs3733829a 19 RAB4B-EGLN2 G A 0.36 0.99 0.85 0.94 0.26
a. SNPs reached genome-wide significance (P value = 5 × 10−8) with smoking behaviors.
b. SNPs did not reach P value of 5 × 10−8.








Male (n, %) 1673 (59.1) 1060 (58.8) 613 (59.7)
Female (n, %) 1157 (40.9) 744 (41.2) 413 (40.3)
Age (mean ± SD) 51.77 ± 13.92 52.03 ± 14.62 51.31 ± 12.59
